Irradiated leukocytes co-infused with bone marrow cells enhance the engraftment in different immunologic organs
| Cells added to BM . | Percentage of donor-derived cells (FVB mice, H-2q) . | |||
|---|---|---|---|---|
| Thymus . | Bone marrow . | Lymph node . | Spleen . | |
| None | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 |
| Irrd. FVB | 100, 99, 100, 0, 0 | 100, 100, 98, 0, 0 | 100, 100, 100, 0, 0 | 100, 100, 100, 0, 0 |
| Irrd. BALB/c | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 |
| Irrd. PBMC | 99, 100, 100, 100 | 98, 100, 100, 100 | 100, 100, 100, 100 | 100, 100, 100, 100 |
| Viable T lymphocytes | ||||
| 104 | 0, 0, 0, 19, 9 | 0, 0, 0, 12, 9 | 0, 11, 15, 91, 33 | 0, 0, 0, 78, 33 |
| 1 × 105 | 100, 100, 100 | 100, 100, 100 | 100, 100, 100 | 100, 100, 100 |
| Cells added to BM . | Percentage of donor-derived cells (FVB mice, H-2q) . | |||
|---|---|---|---|---|
| Thymus . | Bone marrow . | Lymph node . | Spleen . | |
| None | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 |
| Irrd. FVB | 100, 99, 100, 0, 0 | 100, 100, 98, 0, 0 | 100, 100, 100, 0, 0 | 100, 100, 100, 0, 0 |
| Irrd. BALB/c | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 | 100, 0, 0, 0, 100 |
| Irrd. PBMC | 99, 100, 100, 100 | 98, 100, 100, 100 | 100, 100, 100, 100 | 100, 100, 100, 100 |
| Viable T lymphocytes | ||||
| 104 | 0, 0, 0, 19, 9 | 0, 0, 0, 12, 9 | 0, 11, 15, 91, 33 | 0, 0, 0, 78, 33 |
| 1 × 105 | 100, 100, 100 | 100, 100, 100 | 100, 100, 100 | 100, 100, 100 |
Sublethally irradiated BALB/c (H-2d) recipient mice were grafted with 106 bone marrow (BM) cells from FVB (H-2q) mice alone, with irradiated (Irrd.) leukocytes from different origins or with a limited number (104 or 105) of viable donor T lymphocytes purified from spleen using nylon wool columns. Two concentrations of viable donor alloreactive T lymphocytes were shown as control: the highest one favored a persistent full-donor phenotype, the lowest concentration induced only a transient mixed chimerism. At day 45 to day 50 post-BMT, the percentage of donor cells (including both lymphocytes and granulocytes + monocytes) in the different immunologic organs was determined by flow cytometry. Results are from individual recipients.